
Sangram Singh
About Sangram Singh
Data last updated:
Sangram Singh is a Director at Ultra Drugs Private Limited (since 2015), Nominee Director at Ultra Drugs Formulations Private Limited (since 2020) and Director at Viva Drugs Private Limited (since 2025), and holds 2 more current directorships. The companies operate in Pharma, Information Technology and Life Sciences. The 3 current companies with reported revenue have a combined latest revenue of ₹343 Cr; the largest is Ultra Drugs Private Limited at ₹308 Cr (FY 2024). Earlier, Sangram Singh was a Director at Avenue Strategic Consultants Private Limited (2012–2018) and Director at Dakhson Formulations Private Limited (from 2007) and 2 more.
Current companies
| Company | Designation | Appointment | Founded | Revenue | Status |
|---|---|---|---|---|---|
| Director | 30 Jun 2015 | 2005 | ₹308 Cr (FY 2024) | Active | |
| Nominee Director | 04 Feb 2020 | 2020 | ₹24.17 Cr (FY 2024) | Active | |
| Director | 30 Sep 2025 | 1996 | ₹10.80 Cr (FY 2025) | Active | |
| Director | 25 May 2015 | 2015 | Active | ||
| Director | 08 May 2008 | 2008 | Active |
Previous companies
| Company | Designation | Appointment | Founded | Revenue | Status |
|---|---|---|---|---|---|
| Director | 21 Feb 2012 | 2009 | ₹4.73 Cr (FY 2018) | Active | |
| Director | 08 Feb 2007 | 2007 | Strike Off | ||
| Director | 25 May 2007 | 2007 | Strike Off | ||
| Designated Partner | 20 Feb 2013 | 2013 | Strike Off |
Explore Director's current and past company associations Uncover their professional journey today!
Board colleagues of Sangram Singh
| Name | DIN | Company | Designation |
|---|---|---|---|
| Minna Jakhar | 01189282 | Ultra Drugs Private Limited , Ultra Drugs Formulations Private Limited and 3 more | Director |
| Sandeep Kumar Arora | 05312136 | Ultra Drugs Private Limited , Ultra Drugs Formulations Private Limited and 1 more | Director |
| Sonali Dalla | 07045699 | Viva Drugs Private Limited | Director |
Directorship timeline
Open interactive timeline →Shareholding and investment profile for Sangram Singh
Company-level share counts, filed values, and quarterly changes require authenticated premium access.
- Company-level holdings
- Filed share counts
- Reported values
- Quarterly changes
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Sangram Singh
Sangram Singh currently holds 5 directorships: Ultra Drugs Private Limited (Director, since 30 Jun 2015, revenue ₹308 Cr (FY 2024)); Ultra Drugs Formulations Private Limited (Nominee Director, since 04 Feb 2020, revenue ₹24.17 Cr (FY 2024)); Viva Drugs Private Limited (Director, since 30 Sep 2025, revenue ₹10.80 Cr (FY 2025)); Ultra Bytes Private Limited (Director, since 25 May 2015); Dakhson Research & Development Foundation (Director, since 08 May 2008).
Sangram Singh was first appointed on 08 Feb 2007 as Director at Dakhson Formulations Private Limited. The most recent appointment on record is 30 Sep 2025 at Viva Drugs Private Limited.
The 3 current companies of Sangram Singh that report revenue have a combined latest revenue of ₹343 Cr: Ultra Drugs Private Limited ₹308 Cr (FY 2024); Ultra Drugs Formulations Private Limited ₹24.17 Cr (FY 2024); Viva Drugs Private Limited ₹10.80 Cr (FY 2025).
Sangram Singh held 4 earlier board appointments: Avenue Strategic Consultants Private Limited (Director, 21 Feb 2012 to 30 Apr 2018); Dakhson Formulations Private Limited (Director, from 08 Feb 2007); Minson Biosis Private Limited (Director, from 25 May 2007); Able Venture Partners Llp (Designated Partner, from 20 Feb 2013).
The current boards of Sangram Singh's companies include Minna Jakhar (Ultra Drugs Private Limited), Sandeep Kumar Arora (Ultra Drugs Private Limited), Sonali Dalla (Viva Drugs Private Limited).